Cyclin-dependent kinase 1 (CDK1)
Cyclin dependent kinase 1 (CDK1) is a core serine/threonine protein kinase that plays a central role in cell-cycle control, particularly the transition into and progression through mitosis.
Cyclin dependent kinase 1 (CDK1) is a core serine/threonine protein kinase that plays a central role in cell-cycle control, particularly the transition into and progression through mitosis. In normal biology, CDK1 functions as part of the cyclin-dependent kinase network that coordinates DNA replication, checkpoint control, and cell division. Its activity is tightly regulated by cyclins and by inhibitory phosphorylation events, reflecting its importance as a gatekeeper of proliferative progression.
In biomedical research, CDK1 is widely studied as an anticancer target because many tumors depend on dysregulated cell-cycle machinery for continued growth. Recent studies have also linked CDK1 to DNA damage responses and signaling pathways beyond canonical mitotic control, including cGAS-STING-related immune activation and checkpoint kinase regulation. These findings place CDK1 at the intersection of cell-cycle biology, genome stability, and therapeutic vulnerability in cancers such as nasopharyngeal carcinoma, hepatocellular carcinoma, lymphoma, and other invasive malignancies.
Where the papers sit
8 papers from the last 6 months study Cyclin-dependent kinase 1 (CDK1) directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 2 human data · 6 preclinical
Themes one subject
Those 8 are all about one subject.
-
CDK1 Biology and Therapeutics
CDK1 links cell-cycle control to cancer progression, treatment response, and tissue injury. Recurrent mechanisms include Cyclin B1 signaling, Wee1 suppression, mitotic catastrophe, apoptosis, and Drp1-dependent mitochondrial fission. Therapeutic work spans RNAi prodrugs, natural compounds, and selective CDK1 inhibitors designed through molecular modeling. The field remains exploratory, with evidence ranging from cancer-cell studies to diabetic nephropathy and pan-cancer analyses.
Papers
The 8 papers from the last 6 months that study Cyclin-dependent kinase 1 (CDK1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
CDK1 Biology and Therapeutics (8)
- Engineered dual RNAi prodrug for combined suppression of survival and cell cycle pathways in triple negative breast cancer treatment. Chemical communications (Cambridge, England) · 16 Oct 2026 PMID 42885730
- TET2 aggravates podocyte mitotic catastrophe and renal injury in diabetic nephropathy via m5C-dependent downregulation of Wee1 and activation of CDK1-cyclinB1 signaling. Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 5 Sept 2026 PMID 42700265
- β-Elemene Triggers Drp1-Dependent Mitochondrial Fission Through CDK1/Cyclin B1 Signaling in Cervical Cancer Cells. Journal of biochemical and molecular toxicology · 27 Jul 2026 PMID 42506883
- Trichodermin exhibits potent anti-glioblastoma activity by inducing cell cycle arrest and apoptosis, suppressing invasion, and enhancing temozolomide efficacy. Journal of enzyme inhibition and medicinal chemistry · 20 Jul 2026 PMID 42474259
- Investigating the mechanisms of malignant progression in colorectal cancer using weighted gene co-expression network analysis and machine learning. Journal of molecular histology · 18 Jul 2026 PMID 42470494
- Molecular modeling of highly selective CDK1 Inhibitors based on pyrazolo-pyrimidines using 3D-QSAR, docking, and molecular dynamics simulations. PloS one · 22 Jun 2026 PMID 42329991
- Utilizing Molecular Dynamics and Mechanistic Pharmacokinetic Studies in the Design of Selective CDK2 Inhibitors. Journal of medicinal chemistry · 22 Jun 2026 PMID 42328801
- Multi-omics and pan-cancer analysis revealed common molecular signatures to disclose multitargeted anticancer agents through network pharmacology approach. PloS one · 1 Jun 2026 PMID 42224282
By study type
Human data, design not indexed (2)
- Molecular modeling of highly selective CDK1 Inhibitors based on pyrazolo-pyrimidines using 3D-QSAR, docking, and molecular dynamics simulations. PloS one · 22 Jun 2026 PMID 42329991
- Multi-omics and pan-cancer analysis revealed common molecular signatures to disclose multitargeted anticancer agents through network pharmacology approach. PloS one · 1 Jun 2026 PMID 42224282
Preclinical: animal, cell and lab studies (6)
- Engineered dual RNAi prodrug for combined suppression of survival and cell cycle pathways in triple negative breast cancer treatment. Chemical communications (Cambridge, England) · 16 Oct 2026 PMID 42885730
- TET2 aggravates podocyte mitotic catastrophe and renal injury in diabetic nephropathy via m5C-dependent downregulation of Wee1 and activation of CDK1-cyclinB1 signaling. Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 5 Sept 2026 PMID 42700265
- β-Elemene Triggers Drp1-Dependent Mitochondrial Fission Through CDK1/Cyclin B1 Signaling in Cervical Cancer Cells. Journal of biochemical and molecular toxicology · 27 Jul 2026 PMID 42506883
- Trichodermin exhibits potent anti-glioblastoma activity by inducing cell cycle arrest and apoptosis, suppressing invasion, and enhancing temozolomide efficacy. Journal of enzyme inhibition and medicinal chemistry · 20 Jul 2026 PMID 42474259
- Investigating the mechanisms of malignant progression in colorectal cancer using weighted gene co-expression network analysis and machine learning. Journal of molecular histology · 18 Jul 2026 PMID 42470494
- Utilizing Molecular Dynamics and Mechanistic Pharmacokinetic Studies in the Design of Selective CDK2 Inhibitors. Journal of medicinal chemistry · 22 Jun 2026 PMID 42328801
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-07 by GPT. Drafted by language models from published abstracts; not medical advice.